Icon buys Firecrest Clinical to help expand services to pharma firms
Dublin-based Icon said the Firecrest acquisition will expand the range of development services it can offer to the pharmaceutical, biotechnology and medical device industries. Firecrest’s technology boosts investigator site performance and study management.
Icon chief executive, Peter Gray, said: “Delivering consistent, real-time information to sites and a clear path to follow in the conduct of trials not only boosts the quality of trials, it also drives efficiencies and improves study timelines.
